Literature DB >> 12011927

Low frequency of side effects following an incidental 25 times concentrated dose of yellow fever vaccine.

Ana Rabello1, Marcela Orsini, Jolande Disch, Tânia Marcial, Maria da Luz F Leal Md, Marcos da Silva Freire Md, Anna M Yoshida Yamamura, Angelo Viana.   

Abstract

In August/1999, a group of 14 adults from the staff of a private hospital in Contagem - Minas Gerais State, Brazil, received unintentionally a 25 times concentrated dose of the 17-DD yellow fever vaccine (Bio-Manguinhos), due to a mistake at the reconstitution step. All patients were clinically and laboratorially evaluated at days 5, 13 and 35 post vaccination. Frequency of side effects and clinical observations of this group of individuals were not different from the observed in recipients immunized with normal doses of the vaccine. At the second and third evaluation none of the subjects reported symptoms. None of the patients presented abnormalities at the physical examination at none of the time points and in all cases the blood examination was normal, except for a reduced number of platelets that was detected in one subject at the first and second evaluation and reverted to normal at third evaluation. At the first evaluation point, 8 subjects were serum negative and 6 serum positive for yellow fever at the plaque reduction neutralization test. In 5 subjects the observed titre was 10 times higher as the baseline of 2.36 Log10 mUI/ml. The samples collected at second and third evaluation (13th and 35th days) demonstrated that all subjects responded to the vaccination with the exception of one that did not present a positive result in any of the samples collected. This evaluation confirms the safety of the 17-DD yellow fever vaccine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12011927     DOI: 10.1590/s0037-86822002000200008

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  5 in total

1.  Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007-2017.

Authors:  Pedro L Moro; Jorge Arana; Paige L Marquez; Carmen Ng; Faith Barash; Beth F Hibbs; Maria Cano
Journal:  Vaccine       Date:  2019-05-30       Impact factor: 3.641

2.  Serious adverse events associated with yellow fever vaccine.

Authors:  Reinaldo de Menezes Martins; Maria da Luz Fernandes Leal; Akira Homma
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Yellow fever vaccine and risk of developing serious adverse events: a systematic review.

Authors:  Ruben Porudominsky; Eduardo H Gotuzzo
Journal:  Rev Panam Salud Publica       Date:  2018-06-05

4.  17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.

Authors:  Reinaldo M Martins; Maria de Lourdes S Maia; Roberto Henrique G Farias; Luiz Antonio B Camacho; Marcos S Freire; Ricardo Galler; Anna Maya Yoshida Yamamura; Luiz Fernando C Almeida; Sheila Maria B Lima; Rita Maria R Nogueira; Gloria Regina S Sá; Darcy A Hokama; Ricardo de Carvalho; Ricardo Aguiar V Freire; Edson Pereira Filho; Maria da Luz Fernandes Leal; Akira Homma
Journal:  Hum Vaccin Immunother       Date:  2013-01-30       Impact factor: 3.452

5.  Notes from the Field: Errors in Administration of an Excess Dosage of Yellow Fever Vaccine - United States, 2017.

Authors:  Michael M McNeil; Beth F Hibbs; Elaine R Miller; Maria V Cano
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-26       Impact factor: 17.586

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.